Accordingly, CTRP3 and CTRP9 could be potential markers recommended for the clinical use in the diagnosis, prognosis and follow up of patients with T2D at risk of developing CAD. This evidence concerns the gene C1QTNF9 and type 2 diabetes mellitus.